Abstract： Objective： To observe the curative effect of Compound Biejia Ruangan Tablets combined with Entecavir on compensated cirrhosis due to chronic hepatitis B and analyze its effect on liver function and hepatic fibrosis indexes of patients. Methods： A total of 70 cases of patients with compensated cirrhosis due to chronic hepatitis B were selected as the study objects and divided into the Entecavir group and the Biejia Ruangan group on a voluntary basis，with 35 cases in each group. The Entecavir group was treated with Entecavir Tablets，and the Biejia Ruangan group was additionally treated with Compound Biejia Ruangan Tablets based on the treatment of the control group. The treatment lasted for half a year. Clinical effects and the incidence of adverse reactions were compared between the two groups. Liver function and hepatic fibrosis indexes were compared before and after treatment between the two groups. Results： There was no significant difference being found in the comparison of the total effective rates and the total incidence of adverse reactions between the two groups (P＞0.05). After treatment， the levels of total bilirubin (TBil)， alanine transferase (ALT)， and aspartate transferase (AST) in the two groups were decreased (P＜0.05)， and the three levels in the Biejia Ruangan group were lower than those in the Entecavir group (P＜0.05). After treatment， the levels of hyaluronic acid (HA)， laminin (LN)， and type Ⅲ procollagen (PcⅢ) in the two groups were decreased (P＜0.05)，and the three levels in the Biejia Ruangan group were lower than those in the Entecavir group (P＜0.05)；the levels of typeⅣ collagen (Ⅳ- C) in the two groups were increased (P＜0.05)，and the level in the Biejia Ruangan group was higher than that in the Entecavir group (P＜0.05). After treatment， the liver elasticity and stiffness in the two groups were significantly decreased (P＜0.05)， and the liver elasticity and stiffness in the Biejia Ruangan group were lower than those in the Entecavir group (P＜0.05). Conclusion： Compound Biejia Ruangan Tablets combined with Entecavir can significantly improve the liver function of patients with compensated cirrhosis due to chronic hepatitis B and inhibit and reverse the progression of liver fibrosis without increasing adverse reactions.